off-label use of glp-1 agonists for obesity in 2016 Nutritional priorities to support therapy The expanding scope of GLP-1

Hissin, P.J

Thioredoxin-related protein of 14 kDa (TRP14) may be the protein mainly responsible for the reduction of intracellular cystine (Figure 3) [125]

Pathogenesis of white matter changes in cerebral small vessel diseases: Beyond vessel-intrinsic mechanisms

In other words, detoxification is not an option: it is a permanent function, supported by diet, sleep, hydration, and intestinal balance

[21] For patients undergoing surgery , the approach should be individualised based on several factors: Aspiration risk assessment : Patients with symptoms of gastroparesis, those on high doses, or those who have recently initiated therapy may have increased risk Type of surgery : Particularly procedures involving the gastrointestinal tract Indication for GLP-1 therapy : Whether for diabetes management or weight loss If GLP-1 medications are temporarily withheld based on individual risk assessment or local policy, patients with diabetes should have a clear plan for glycaemic management, including capillary glucose monitoring and potential bridging therapy, developed in consultation with the diabetes team